Sniženje vrednosti supresorskih ćelija mijeloidnog porekla kod bolesnika sa melanomom indukovano interferonom alfa

  • Ivan Stanojević Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Institute for Medical Research,Military Medical Academy, Belgrade, Serbia
  • Milomir Gačević Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Clinic for Plastic and Reconstructive Surgery, Military Medical Academy, Belgrade, Serbia
  • Milena Jović Institute for Pathology, Military Medical Academy, Belgrade, Serbia
  • Željko Mijušković Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Clinic for Dermatovenerology, Military Medical Academy, Belgrade, Serbia
  • Radoš Zečević Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Clinic for Dermatovenerology, Military Medical Academy, Belgrade, Serbia
  • Lidija Zolotarevski Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Institute for Pathology, Military Medical Academy, Belgrade, Serbia
  • Ljiljana Jauković Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Institute for Nuclear Medicine, Military Medical Academy, Belgrade, Serbia
  • Milica Rajović Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Clinic for Plastic and Reconstructive Surgery, Military Medical Academy, Belgrade, Serbia
  • Marijan Novaković Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Clinic for Plastic and Reconstructive Surgery, Military Medical Academy, Belgrade, Serbia
  • Karolina Miller Department of Histopathology, Dorset County Hospital NHS Foundation Trust, Dorchester, United Kingdom
  • Ivana Binić Faculty of Medicine, University of Niš, Niš, Serbia
  • Danilo Vojvodić Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Institute for Medical Research,Military Medical Academy, Belgrade, Serbia
DOI: https://doi.org/10.2298/5483
Ključne reči: melanoma||, ||melanom, myeloid cells||, ||ćelije, mijeloidne, interferon-alpha||, ||interferon-alfa,

Sažetak


Uvod/Cilj. Interakcija između tumorskih ćelija i imunoregulatornih ćelija domaćina u stvaranju mikrookruženja koje pospešuje progresiju tumora nalazi se u žiži brojnih istraživanja poslednjih godina. Supresorske ćelije mijeloidnog porekla predstavljaju heterogenu populaciju nezrelih dendritičnih ćelija, makrofaga i granulocita. Kod bolesnika sa tumorom ove ćelije akumuliraju se u tumorskom mikrookruženju, drenažnim limfnim čvorovima, perifernoj krvi i jetri i njihov broj koreliše sa stadijumom bolesti i metastatskom bolešću. Cilj rada bio je ispitivanje efekata interferona alfa na procentualnu zastupljenost supresorskih ćelija mijeloidnog porekla u perifernoj krvi bolesnika sa melanomom. Metode. Bolesnici lečeni interferonom dobijali su interferon alfa potkožno, u optimalnim dozama, najmanje šest meseci pre izvođenja analize. Uzorci krvi uzimani su od bolesnika sa melanomom (n = 91) i zdravih kontrola (n = 8) sličnog uzrasta i pola. Sledeća antihumana monoklonska antitela korišćena su za imunofenotipizaciju: anti-CD15-FITC, anti-CD33-PE, anti-CD45-ECD, anti-HLA-DR PE/Cy5, anti-CD14-FITC, anti-CD16-PE i anti-CD11b-PE. Rezultati. Poređenjem vrednosti supresorskih ćelija mijeloidnog porekla između bolesnika u 2. stadijumu melanoma koji jesu i bolesnika koji nisu lečeni interferonom alfa, nije utvrđena statistički značajna razlika. Kada smo uporedili vrednosti supresorskih ćelija mijeloidnog porekla kod bolesnika u 3. stadijumu melanoma pronašli smo značajnu razliku u vrednostima granulocitne podgrupe ovih ćelija između grupe lečenih i grupe nelečenih interferonom alfa. Poređenjem vrednosti svih populacija ovih supresorskih ćelija između bolesnika lečenih interferonom alfa i zdravih osoba utvrđene su značajno više vrednosti supresorskih ćelija kod bolesnika sa melanomom. Granulocitne i ukupne supresorske ćelije mijeloidnog porekla bile su značajno niže kod bolesnika sa progresijom melanoma koji su lečeni interferonom alfa nego kod bolesnika sa stabilnom bolešću koji nisu lečeni interferonom alfa. Zaključak. Interferon alfa dovodi do sniženja vrednosti supresorskih ćelija mijeloidnog porekla kod bolesnika u 3. stadijumu melanoma. Takođe, utvrdili smo povratak visokih vrednosti ovih supresorskih ćelija nakon mnogo meseci od prestanka terapije interferonom alfa.

 

Reference

Scolyer RA, Long GV, Thompson JF. Evolving concepts in me-lanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol 2011; 5(2): 124−36.

Bizhan B, Linglei M, Roya N, Arun S, Golnar R. From Melanocyte to Metastatic Malignant Melanoma. Dermatol Res Pract 2010; 2010: 583748.

Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19(6): 3635−48.

Mukherji B. Immunology of melanoma. Clin Dermatol 2013; 31(2): 156−65.

Ilkovitch D, Lopez DM. Immune modulation by melanoma-derived factors. Exp Dermatol 2008; 17(12): 977−85.

Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16(4): 348−53.

Abbas A, Lichtman A, Pillai S. Cellular and molecular immu-nology. 7th ed. Saunders Elsevier; 2012. p. 389−405.

Lechner MG, Liebertz DJ, Epstein AL. Characterization of cy-tokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185(4): 2273−84.

Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66(18): 9299−307.

Motzer RJ, Hutson TE, Tomczak P, Michaelson M, Bukowski RM, Oudard S, et al. Overall survival and updated results for suni-tinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584−90.

Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N, et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009; 9(4): 470−81.

Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, et al. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother 2010; 33(8): 817−27.

Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived Suppressor Cells in Cancer Patients: A Clinical Perspective. J Immunother 2012; 35(2): 107−15.

Frank SJ, Meyers M. Interferon as adjuvant therapy for high risk melanoma. Melanoma Lett 1995; 13: 1−4.

Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14(1): 7−17.

Sabel MS, Sondak VK. Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma. Oncologist 2003; 8(5): 451−8.

Hauschild A. Adjuvant Interferon alfa for melanoma: new evidence-based treatment recommendations. Curr Oncol 2009; 16(3): 3−6.

Zoglmeier C, Bauer H, Nörenberg D, Wedekind G, Bittner P, Sand-holzer N, et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 2011; 17(7): 1765−75.

Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother 2012; 35(9): 702−10.

Mohamed SL, Abdel-Aziz ZA, Senna MA, Al-Azm AR, Albatei H, Aldemelaawy M, et al. Frequencies of circulating myeloid derived suppressor cells and dendritic cells in Egyptian patients with chronic Hepatitis C Virus infection undergoing treatment with IFN-α-based therapy. J Immunother Cancer 2013; 1(Suppl 1): P248.

Dickson PV, Gershenwald JE. Staging and prognosis of cuta-neous melanoma. Surg Oncol Clin N Am 2011; 20(1): 1−17.

Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 2000; 88(5): 1063−71.

Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et al. Evidence-based and interdisciplinary con-sensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res 2008; 18(2): 152−60.

Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, et al. Short German guidelines: malignant me-lanoma. J Dtsch Dermatol Ges 2008; 6 Suppl 1: S9−S14. (German)

Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III mela-noma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372(9633): 117−26.

Sondak VK, Flaherty LE. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for. Lancet 2008; 372(9633): 89−90.

Kimberly JR, Amaria RN, Ramirez O, Callihan EB, Gao D, Borakove M, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother 2013; 62(11): 1711−22.

Objavljeno
2015/07/08
Broj časopisa
Vol. 72 Br. 4 (2015)
Rubrika
Originalni članak